Buy Tesamorelin by Dragon Pharma at Best Anabolic Steroids. The pack holds one lyophilised vial with 5 mg of tesamorelin, a stabilised analogue of growth hormone releasing hormone, so the strength you actually work with depends on how much solvent you add rather than on a fill line. The approved injectable form of this molecule - sold as Egrifta for excess visceral fat in lipodystrophy - is the reason human data exist for it at all; the vial on this page is a research material rather than that pharmaceutical presentation, and this description keeps the two apart throughout.
It is a peptide for a sustained routine, not a short push, and the numbers further down explain why.
Product Overview
What arrives is a single glass vial of lyophilised powder: 5 mg of tesamorelin peptide, sealed, produced under GMP conditions, with the mass of active material stated on the label. It is not a ready-to-inject solution and there is no solvent in the box, so the buyer supplies bacteriostatic water and calculates the concentration from the volume added. A 5 mg vial reconstituted with a stated volume gives a fixed number of doses at a fixed strength, which is why the arithmetic matters more here than the label figure.
Tesamorelin is a GHRH analogue, which puts it in the signalling layer above growth hormone rather than in the hormone itself. The stabilised version is what separates it from older GHRH peptides: the same family, but a different stability profile and a very different evidence base. Its approved clinical use - reduction of visceral adipose tissue in patients with lipodystrophy - is what makes it unusual among research peptides, because that approval required human trials rather than anecdote.
Two limits belong in the same paragraph as the strengths. The approved population is narrow, and transferring those results to healthy trained users is not confirmed by any source behind this page. And one 5 mg vial does not cover a week at the approved 2 mg daily step, which is arithmetic rather than a comment on quality.
Mechanism of Action
The peptide binds the GHRH receptor on pituitary somatotrophs and drives release of the body's own growth hormone in pulses, which in turn lifts hepatic IGF-1. That is the opposite approach to supplying recombinant hormone from outside, the route taken by Dragontropin HGH, and it is also different from secretagogues that act on the ghrelin receptor, such as Ipamorelin and Hexarelin. Same end signal, three different doors.
Exposure time is the practical constraint. General reference data put the elimination half-life between 26 and 38 minutes; the label for the SV presentation reports an average of about 8 minutes after a 1.4 mg subcutaneous dose, and the older WR form is listed near 11 minutes. Nothing in that range supports infrequent administration, so the protocol is daily by necessity.
The clinical endpoint was fat, and specifically visceral fat, measured over long daily programmes rather than weeks. IGF-1 rises within hours of a dose while the fat change accumulates over months, so the two markers move on completely different clocks and only one of them is useful for judging a single injection.
What to Expect from a Tesamorelin Routine
- Growth hormone and IGF-1 rise within hours of a subcutaneous dose, and the response is read on the IGF-1 axis rather than felt.
- Visceral fat is the endpoint that moved in clinical work, and it moved over months of daily use, not over a single week.
- Consistency beats escalation. Because the peptide clears in minutes, timing discipline matters more than pushing the amount up.
- Supply planning is part of the protocol: a 5 mg vial runs out well inside a week at the approved 2 mg daily step.
- Class effects are dose related: edema, fluid retention, joint aches and injection site reactions are described for GH peptides generally.
- Tesamorelin is banned at all times under WADA class S2, where it is named directly, which matters to any tested athlete.
Dosing Steps and What One 5 mg Vial Covers
There is no separate research dosing convention for this compound, so the table keeps approved clinical steps apart from what a single vial can deliver.
| Approved step | 2 mg subcutaneously once daily in the original Egrifta label |
| Lower approved step | 1.4 mg once daily for the SV presentation, with an average half-life near 8 minutes |
| Frequency | Daily; elimination runs from about 8 minutes to 38 minutes, so a weekly injection is not supported |
| One 5 mg vial | Does not cover a week at 2 mg per day - arithmetic, not a statement about potency |
| Female | No verified protocol for women appears anywhere in the source material behind this page |
| Administration | Subcutaneous; the approved site is the abdomen and the injection point moves with every dose |
Readers who want a GHRH signal with far fewer injections look at CJC-1295 DAC, whose release profile is measured in days rather than minutes. Readers whose target is fat mass through a different mechanism altogether look at a GLP-1 material such as Tirze-Pep 5mg, or at the 176-191 fragment in AOD 9604 5mg.
Combining Tesamorelin with Other Peptides
Three arrangements come up in the sources and in the way this class is studied. The pattern in all of them is daily use over a long window rather than a four-week block.
One comparison is not a stack and is worth stating plainly: recombinant HGH supplies the hormone itself, while this peptide only asks the pituitary for more of it, and IGF-1 LR3 sits one step further downstream entirely.
Reconstitution Arithmetic and IGF-1 Follow-Up
There is no reset step to plan for this compound. Tesamorelin drives growth hormone release through the pituitary and leaves the gonadal axis untouched, so no SERM protocol exists for it; what has to be planned instead is the vial and the monitoring.
Tesamorelin Side Effects and Management
The profile follows the GH peptide class more than the molecule itself, and most entries respond to dose adjustment.
Storing the Tesamorelin Vial and the Mixed Solution
Keep the lyophilisate cold, dry and in its carton, and give the reconstituted solution the refrigerator rather than the shelf: the sources describe no long room temperature window for a mixed peptide solution. Because the peptide clears in minutes, the bottle is the fragile part of the routine, not the molecule. Add the solvent gently down the wall of the vial instead of shaking it, mark the mixing date on the label, and do not refreeze a thawed or mixed vial. Draw each dose with a fresh needle, wipe the stopper with an alcohol swab before entry, keep the vial away from light and out of the reach of children, and dispose of used vials and sharps as medicinal waste under local rules.
Buying Tesamorelin Online
Because the useful facts about this peptide are short and unglamorous - a real approval, a real population, a half-life measured in minutes and a 5 mg vial that does not last a week - and this page states them instead of promising a transformation. The vial is Dragon Pharma tesamorelin at 5 mg of lyophilised powder. Packaging is lab tested and delivery follows the site's usual international and US terms, and the description tells you what the clinical work actually measured so you can decide whether a daily routine fits.
